|

Bcl-XL Proteolysis Targeting Chimera DT2216 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: APTaD DT2216, Antiapoptotic Protein Targeted Degrader DT2216, BCL-XL-specific PROTAC DT2216, Bcl-XL Degrader DT2216, Bcl-XL PROTAC DT2216 +6 more

Pipeline

Phase 1/2: 1

Top Sponsors

  • Children's Oncology Group1

Indications

  • Refractory Fibrolamellar Carcinoma1
  • Refractory Childhood Fibrolamellar Carcinoma1
  • Recurrent Fibrolamellar Carcinoma1
  • Recurrent Childhood Fibrolamellar Carcinoma1
  • Childhood Fibrolamellar Carcinoma1

Birmingham, Alabama1 trial

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Children's Hospital of Alabama

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.